Azra AI, RevealDx partner on lung nodule AI

Azra AI and RevealDx have entered a partnership to integrate RevealAI-Lung into Azra AI’s enterprise incidental findings and oncology workflow platform. RevealDx announced the partnership May 14.

RevealAI-Lung characterizes incidental lung nodules by producing a Malignancy Similarity Index score, according to RevealDx. The company said the score is intended to help radiologists make follow-up recommendations for cancer diagnosis.

FDA documentation describes the software as a computer-aided diagnostic application for incidentally detected lung nodules on CT scans. The mSI score is indicated for pulmonary nodules measuring 6 mm to 15 mm in patients ages 18 years and older.

Clinical users retain responsibility for diagnosis and patient management, according to the FDA summary. The document also states that the mSI score is not a probability of malignancy and is not indicated for lung cancer screening.

RevealDx said the software has been validated on more than 1,500 patients from multiple cohorts. The company also said RevealAI-Lung is reimbursable by Medicare using codes 0721T and 0722T.

Azra AI said the integration builds on its acquisition of Thynk Health, a company focused on lung cancer screening and incidental findings management. That acquisition was announced April 28.

The combined workflow is intended to help customers identify high-risk nodules, manage patients through diagnosis, and connect them to oncology workflow automation, according to the companies.